also monitored. Results-Follow up was a mean of 12.3 (SD 4.0) months and ranged from 7 to 17 months. A successful reduction in inflammation was recorded in 22/39 eyes (56%) and 10120 patients (50%). This improvement occurred within 1 month in 64% and in all by 2 months. Three patients developed allergy. Other side effects included nausea (n=3), headache (n=l), urinary hesitancy (n=l), and mild lymphocytopenia (n=l). These This prospective study aimed to assess the role of oral sulphapyridine in OCP. Sulphapyridine has not previously been used for OCP, but it has been successful in other inflammatory dermatoses67 and in rheumatoid arthritis." It has also been used for inflammatory bowel disease when combined with 5-aminosalicylic acid (5-ASA).12-15 Sulphapyridine was chosen for the study because it is an effective anti-inflammatory and immunosuppressive agent for similar diseases and has fewer side effects than the existing agents.
Materials and methods
Patients were selected for the study from the corneal and external disease clinics at Moorfields Eye Hospital over the 18 month period from September 1992. All patients with OCP were categorised from 0 to 4+ by the amount of conjunctival inflammation. These were defined as mild (+), conjunctival hyperaemia only; moderate (++), hyperaemia with conjunctival oedema; marked (+++), significant conjunctival stromal and epithelial oedema; severe (++++), very oedematous conjunctival stroma and epithelium in four quadrants.2 16 The inclusion criteria were all patients with OCP who had 'moderate' to 'marked' ocular inflammation that had either failed to respond to topical treatment (n= 17) or dapsone (n=3). All patients were consecutive and there were no exclusions. Tables 1 and 2. These groups exclude three cases of allergy because the treatment duration was too short to assess its effect. The one eye that initially had only mild (+) inflammation had total resolution of the inflammation. Only Mondino's staging was useful at discriminating between the two groups because of the predominance of Sulphapyridine-a new agentfor the treatment ofocular cicatricial pemphigoid was also associated with a lower response rate; 2/22 successful cases versus 4/11 unsuccessful cases (NS, p>0.05)( Table 1) . The side effects are detailed in Table 3 . All cases of allergy presented as a skin rash between 2 and 3 weeks after starting sulphapyridine and required discontinuation of the treatment. By reducing the dose to 500 mg once daily, the nausea resolved completely in two patients and was tolerable in the other. All other patients were maintained on 500 mg twice daily. Two of these patients had a continued therapeutic effect on this dose, the other failed to improve on either dose.
During the study three patients died. Two were still taking sulphapyridine at the time of their death, 10 and 12 months later. The other patient had no improvement from 6 months of treatment and died 4 months after its cessation. These patients were 78, 84, and 84 years old and the causes of death were myocardial infarct, 'died in sleep', and cardiovascular accident respectively. The objective of this study was to find an agent that was effective at resolving the ocular inflammation but had fewer short term and long term side effects than existing agents. For moderate to marked ocular inflammation, the current drug of choice is dapsone. In severe inflammation, cyclophosphamide is the most effective although other immunosuppressive drugs may be therapeutic.2' 18 20 21 Dapsone is a sulphone that inhibits the myeloperoxidase enzyme system of polymorphonuclear leucocytes, suppresses the migration of neutrophils, and stabilises lysosomal membranes.22 23The clinical response is mainly due to inhibition of neutrophil recruitment and function. In OCP, partial or complete improvement of ocular inflammation occurs in 70-71% and is apparent rapidly, 55% within 4 weeks.2 24 Over a mean of 35 months, the disease is controlled in 45%. Severe inflammation responds poorly.20 Side effects may be marked, the most significant of which is chronic haemolysis with 95% of patients having a 1.0-3.4 g/dl decrease in haemoglobin.2 Other effects include nausea (20%), abdominal pain (10%), peripheral neuropathy (5%), and hepatitis (5%). 2 Cyclophosphamide has been successful in treating severely inflamed conjunctiva in OCP but it is particularly toxic.2 18 In one ocular series, 100% developed some degree of anaemia, 83% developed alopecia, 8% developed haematuria, and 8% developed leucopenia.2 There is also a long term risk of malignancy.25 26 These drugs contrast with sulphapyridine which has less serious side effects. In this series, the commonest was allergy which prevented its use in 15%. Nausea was present in 15% but this responded to dose reduction. There are no long term risks of malignancy or risks of Stevens-Johnson syndrome. ' 
